Lifecore Biomedical Signs CDMO Agreement with Multinational Pharmaceutical Company-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Lifecore Biomedical Signs CDMO Agreement with Multinational Pharmaceutical Company

Reuters2025-12-17

<a href="https://laohu8.com/S/LFCR">Lifecore Biomedical</a> Signs CDMO Agreement with Multinational Pharmaceutical Company

Lifecore Biomedical Inc. announced that it has signed a contract development and manufacturing organization $(CDMO)$ master services agreement with a new large multinational pharmaceutical customer. Under the agreement, Lifecore will provide development services and manage the technology transfer for an injectable pharmaceutical product, with the goal of moving commercial supply from overseas facilities to Lifecore's own facilities. Upon completion of the transfer and satisfaction of regulatory requirements, Lifecore expects to become the commercial supplier for the product. The company stated that the size of the partner's program positions it to become one of Lifecore's top five commercial customers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603445) on December 17, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2592799280?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 20:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592799280","market":"us","top_or_hot":-1,"title":"Lifecore Biomedical Signs CDMO Agreement with Multinational Pharmaceutical Company","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LFCR\">Lifecore Biomedical</a> Signs CDMO Agreement with Multinational Pharmaceutical Company\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lifecore Biomedical Inc. announced that it has signed a contract development and manufacturing organization <a href=\"https://laohu8.com/S/CDMO\">$(CDMO)$</a> master services agreement with a new large multinational pharmaceutical customer. Under the agreement, Lifecore will provide development services and manage the technology transfer for an injectable pharmaceutical product, with the goal of moving commercial supply from overseas facilities to Lifecore's own facilities. Upon completion of the transfer and satisfaction of regulatory requirements, Lifecore expects to become the commercial supplier for the product. The company stated that the size of the partner's program positions it to become one of Lifecore's top five commercial customers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603445) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lifecore Biomedical Signs CDMO Agreement with Multinational Pharmaceutical Company</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifecore Biomedical Signs CDMO Agreement with Multinational Pharmaceutical Company\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-17 20:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/LFCR\">Lifecore Biomedical</a> Signs CDMO Agreement with Multinational Pharmaceutical Company\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lifecore Biomedical Inc. announced that it has signed a contract development and manufacturing organization <a href=\"https://laohu8.com/S/CDMO\">$(CDMO)$</a> master services agreement with a new large multinational pharmaceutical customer. Under the agreement, Lifecore will provide development services and manage the technology transfer for an injectable pharmaceutical product, with the goal of moving commercial supply from overseas facilities to Lifecore's own facilities. Upon completion of the transfer and satisfaction of regulatory requirements, Lifecore expects to become the commercial supplier for the product. The company stated that the size of the partner's program positions it to become one of Lifecore's top five commercial customers.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603445) on December 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4212","symbol_name":"包装食品与肉类","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5Brwr0:1","article_id":"2592799280","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592799280","pubTimestamp":1765972897,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lifecore Biomedical Inc. announced that it has signed a contract development and manufacturing organization  master services agreement with a new large multinational pharmaceutical customer. Under the agreement, Lifecore will provide development services and manage the technology transfer for an injectable pharmaceutical product, with the goal of moving commercial supply from overseas facilities to Lifecore's own facilities. Upon completion of the transfer and satisfaction of regulatory requirements, Lifecore expects to become the commercial supplier for the product. The company stated that the size of the partner's program positions it to become one of Lifecore's top five commercial customers.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal ad","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4212":"包装食品与肉类","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","BK4121":"生命科学工具和服务","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4588":"碎股","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LFCR":"LIFECORE BIOMEDICAL INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC"},"translate_title":"Lifecore Biomedical与跨国药企签署CDMO协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LFCR":0.9,"NDAQ":0.9},"content_text":"Lifecore Biomedical Signs CDMO Agreement with Multinational Pharmaceutical Company\n    \n\n        Lifecore Biomedical Inc. announced that it has signed a contract development and manufacturing organization $(CDMO)$ master services agreement with a new large multinational pharmaceutical customer. Under the agreement, Lifecore will provide development services and manage the technology transfer for an injectable pharmaceutical product, with the goal of moving commercial supply from overseas facilities to Lifecore's own facilities. Upon completion of the transfer and satisfaction of regulatory requirements, Lifecore expects to become the commercial supplier for the product. The company stated that the size of the partner's program positions it to become one of Lifecore's top five commercial customers.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifecore Biomedical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9603445) on December 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}